Clinical Trials Logo

Clinical Trial Summary

The aim of this study is to test the potentially protective role of myonectin in patients with a first episode of ST elevation myocardial infarction (MI) treated with primary percutaneous coronary intervention (PCI). The main questions which are assumed to be answered after study completion: 1. Does higher myonectin concentration influence the in-hospital and 30-day course of the first ST-elevation MI in patients treated with primary coronary angioplasty 2. Is there a relationship between the serum myonectin concentration, related to patient's nutritional status and physical activity with the patient's physical activity declared as usually before the coronary event occurrence, the cardiac biomarkers level, and myocardial and skeletal muscle mass determined in order to objectify the relationship of physical activity before the infarction with 30-day and one-year mortality, and the other primary and secondary outcomes measured at 12-month visit, e.g. the extent of myocardial infarction, 3. Is there a relationship between the baseline concentration of myonectin and troponin with the control of atherosclerosis risk factors, declared physical activity and parameters of body composition, outcome of treadmill exercise test, values of echocardiographic parameters and myonectin concentration 12 months after a cardiovascular incident


Clinical Trial Description

Myonectin or Complement C1q Tumor Necrosis Factor - Related Protein 15 (CTRP15) is a cytokine secreted by skeletal muscle. The participation of myonectin in the regulation of lipid homeostasis in the liver and adipose tissue has been proven. The concentration of myonectin depends on the nutritional status of the organism, it decreases during fasting and increases after feeding. In studies on mice, a protective effect of high concentrations of myonectin on the course of myocardial infarction was observed. The effect of regular physical exercise on the concentration of myonectin in the serum was also demonstrated. Abnormal function of myokines, including myonectin, has also been linked to sarcopenia, which significantly negatively affects the prognosis of patients with heart failure. Potentially protective properties of myonectin in the case of ischemia-reperfusion injury in the course of myocardial infarction have not been studied in humans so far. Myonectin may become a potentially useful prognostic indicator of the severity of myocardial infarction. It may also potentially become a target for a new cardioprotective therapy in patients with acute myocardial ischaemia. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05700773
Study type Observational
Source Wojewodzki Szpital Zespolony w Elblagu
Contact Michal Jaskiewicz, MD
Phone +48 606613129
Email mich.jask@gmail.com
Status Recruiting
Phase
Start date January 1, 2023
Completion date May 31, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05601999 - Study of Efficacy and Safety of GNR-060 vs Metalyse in Patients With ST Elevation Myocardial Infarction Phase 3
Recruiting NCT06147986 - Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells as an Add-On Treatment for Acute ST-elevation Myocardial Infarction (STEMI) Patients Phase 2
Not yet recruiting NCT05881382 - Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction Phase 3
Enrolling by invitation NCT02615015 - SNPs in the DNase 1 Gene Impair Its Activity and Are Increased in a STE-ACS Patient Cohort Compared to Healthy Controls N/A
Recruiting NCT05812963 - IVUS Versus FFR for Non-infarct Related Artery Lesions in Patients With Multivessel Disease and Acute STEMI N/A
Recruiting NCT05554588 - Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI N/A
Recruiting NCT05450757 - Shanghai ST-segment Elevation Myocardial Infarction Cohort
Active, not recruiting NCT03278509 - Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART) Phase 4
Completed NCT03156699 - The Incidence, Effect and Persistence of Fragmented-QRS, in Patients Presenting With ST-Elevation Myocardial Infarction
Not yet recruiting NCT03266328 - Procedure and In-hospital Outcome of Patients Under 40 Years Old Undergoing Primary Percutaneous Coronary Intervention for Acute ST Elevated Myocardial Infarction in Assiut University N/A
Not yet recruiting NCT03263468 - Revascularization StrategIes for ST Elevation Myocardial Infarction Trial N/A
Enrolling by invitation NCT04970238 - Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction Phase 4
Recruiting NCT02557217 - NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction Phase 2
Recruiting NCT02224534 - Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction Phase 4
Completed NCT01136187 - Trial Comparing Radial and Femoral Approach in Primary Percutaneous Coronary Intervention (PCI) N/A
Not yet recruiting NCT04068116 - Impact of Ischemic Post-conditioning N/A
Not yet recruiting NCT04063345 - Long-term Clinical Outcomes of intraVascular Ultrasound-guided vs Angiography-guided Primary pErcutaneous Intervention in Patients With Acute ST Segment Elevated Myocardial Infarction Phase 2/Phase 3
Active, not recruiting NCT03646357 - BEtablocker Treatment After Acute Myocardial Infarction in Patients Without Reduced Left Ventricular Systolic Function Phase 4
Completed NCT03740776 - The Eosinophils Percentage Predicts In-hospital Major Adverse Cardiac Events in STEMI Patients After PCI
Completed NCT03984071 - The Predictive Value of eGFR for Adverse Cardiovascular Events in Patients With STEMI